JointHealth™ express August 12, 2014
What has ACE done for you lately? Here’s what we’ve been up to this month!
In July’s roundup of ACE’s current projects, we highlight our campaigns in the workplace, promoting patient input, and arthritis research.
Last week to apply for the “Canada’s Best Workplaces for Employees Living with Arthritis” awards!
The “Canada’s Best Workplaces for Employees Living with Arthritis Awards” is a national search to find and recognize small, medium and large companies or organizations who offer exceptional workplaces for their employees living with arthritis.
We are interested in learning about your workplace. If you are an employer or employee, we encourage you to complete this survey to assess your company’s arthritis friendliness. By completing the application, you will reinforce practices you are already doing well and, at the same time, identify exciting new opportunities for improvement for your employees with arthritis. The Awards will look at organizational benefits, physical workplace, and employee education.
ACE is seeking patient input for tofacitinib, tocilizumab, and certolizumab pegol
To help the Canadian Agency for Drugs and Technologies (CADTH) make their drug recommendations, the Common Drug Review (CDR) accepts input from patient groups like Arthritis Consumer Experts (ACE). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides drug formulary recommendations to the publicly funded drug plans in Canada (except Quebec). Because patient input is vitally important to government decision-making about medications, ACE would like to gather your views and share them with the CDR.
ACE is currently welcoming patients and their caregivers to provide input on the manufacturer’s submission for tofacitinib (Xeljanz®) for the treatment of rheumatoid arthritis (RA), the subcutaneous (an injection under the skin) tocilizumab (Actemra®) for the treatment of RA, and the intravenous (IV) form of certolizumab pegol (Cimzia®) for the treatment of ankylosing spondylitis. The deadline for the patient input submission is Thursday, August 28, 2014.
ICON Boot Camp for Research
ICON (Improving Cognitive & Joint Health Network) is a 3-year knowledge translation network research study funded by the Canadian Institutes of Health Research. The research is aimed to optimize mobility of older Canadians by modernizing the process of knowledge translation, enhance brain and joint health by improving physical activity, and improve the timely use of first-line treatment in the management of osteoarthritis and rheumatoid arthritis.
As the leader of the Knowledge User Advisory Committee, ACE attended a two-day ICON Boot Camp on July 24 and 25, along with representatives and experts from the Alzheimer Society of British Columbia, the Mary Pack Arthritis Program, the Arthritis Research Centre of Canada, Kinduct Technologies, QxMD, GRAND NCE, the Centre for Digital Media, the Arthritis Health Professions Association, and the Canadian Association for Retired Persons met to discuss ways to improve the transfer of healthcare information to improve bone and joint health.
The ICON team looks forward to new developments in the use of digital media for research and knowledge translation. ACE will share more research information as the ICON study advances.
What has ACE done for you lately? Here’s what we’ve been up to this month!
In July’s roundup of ACE’s current projects, we highlight our campaigns in the workplace, promoting patient input, and arthritis research.
Last week to apply for the “Canada’s Best Workplaces for Employees Living with Arthritis” awards!
The “Canada’s Best Workplaces for Employees Living with Arthritis Awards” is a national search to find and recognize small, medium and large companies or organizations who offer exceptional workplaces for their employees living with arthritis.
We are interested in learning about your workplace. If you are an employer or employee, we encourage you to complete this survey to assess your company’s arthritis friendliness. By completing the application, you will reinforce practices you are already doing well and, at the same time, identify exciting new opportunities for improvement for your employees with arthritis. The Awards will look at organizational benefits, physical workplace, and employee education.
ACE is seeking patient input for tofacitinib, tocilizumab, and certolizumab pegol
To help the Canadian Agency for Drugs and Technologies (CADTH) make their drug recommendations, the Common Drug Review (CDR) accepts input from patient groups like Arthritis Consumer Experts (ACE). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides drug formulary recommendations to the publicly funded drug plans in Canada (except Quebec). Because patient input is vitally important to government decision-making about medications, ACE would like to gather your views and share them with the CDR.
ACE is currently welcoming patients and their caregivers to provide input on the manufacturer’s submission for tofacitinib (Xeljanz®) for the treatment of rheumatoid arthritis (RA), the subcutaneous (an injection under the skin) tocilizumab (Actemra®) for the treatment of RA, and the intravenous (IV) form of certolizumab pegol (Cimzia®) for the treatment of ankylosing spondylitis. The deadline for the patient input submission is Thursday, August 28, 2014.
ICON Boot Camp for Research
ICON (Improving Cognitive & Joint Health Network) is a 3-year knowledge translation network research study funded by the Canadian Institutes of Health Research. The research is aimed to optimize mobility of older Canadians by modernizing the process of knowledge translation, enhance brain and joint health by improving physical activity, and improve the timely use of first-line treatment in the management of osteoarthritis and rheumatoid arthritis.
As the leader of the Knowledge User Advisory Committee, ACE attended a two-day ICON Boot Camp on July 24 and 25, along with representatives and experts from the Alzheimer Society of British Columbia, the Mary Pack Arthritis Program, the Arthritis Research Centre of Canada, Kinduct Technologies, QxMD, GRAND NCE, the Centre for Digital Media, the Arthritis Health Professions Association, and the Canadian Association for Retired Persons met to discuss ways to improve the transfer of healthcare information to improve bone and joint health.
The ICON team looks forward to new developments in the use of digital media for research and knowledge translation. ACE will share more research information as the ICON study advances.
Arthritis Consumer Experts
ACE thanks Arthritis Research Canada (ARC) for its scientific review of ACE and JointHealth™ information and education programs.